Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder

Bibliography

• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Press, Inc. (1994).
   Google Scholar
• ENDICOTT J, HARRISON W: Daily Rating of Severity of Problems Form. Department of Research Assessment and Training, New York State Psychiatric Institute, New York, NY, USA (1990).
   Google Scholar
• ENDICOTT J, NEE J, COHEN J, HALBREICH U: Premenstrual changes: patterns and correlates of daily ratings.' Affect. Diserd. (1986) 10(2):127–135.
   Google Scholar
• RIVERA-TOVAR AD, PILKONIS P, FRANK E: Symptom patterns in late luteal-phase dysphoric disorder. I Psychepathel. Behav. Assess. (1992) 14(2):189–199.
   Web of Science ®Google Scholar
• HALBREICH U, ENDICOTT J, SCHACHT S, NEE J: The diversity of premenstrual changes as reflected in the Premenstrual Assessment Form. Acta Psychiatr. Scand. (1982) 65(1):46–65.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, DERUBEIS RJ, RICKELS K: Reliability and validity of a daily diary for premenstrual syndrome. Psych Res. (1996) 65(2):97–106.
   PubMed Web of Science ®Google Scholar
• REID RL: Premenstrual syndrome. Carr: Pre& Obstet. Gynecel. Feral (1985) 8:1–57.
   Google Scholar
• MORTOLA JF, GIRTON L, BECK L, YEN SS: Diagnosis of premenstrual Gin. Psych. (2000) 61 (Suppl. 12):17–21.
   Google Scholar
• RUBINOW DR, ROY-BYRNE P, HOBANMC, GOLD PW, POST RIVI: Prospective assessment of menstrually related mood disorders. Am.j Psych. (1984) 141(5):684–686.
   PubMed Web of Science ®Google Scholar
• ROCA CA, SCHMIDT PJ, BLOCH M, RUBINOW DR: Implications of endocrine studies of premenstrual syndrome. Psych. Ann. (1996) 26(9):576–580.
   Web of Science ®Google Scholar
• SCHMIDT PJ, NIEMAN LK, DANACEAU MA, ADAMS LF, RUBINOW DR: Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl. I Med. (1998) 338(4):209–216.
   PubMed Web of Science ®Google Scholar
• SUNDSTROM I, BACKSTROM T, WANG M, OLSSON T, SEIPPEL L, BIXO M: Premenstrual syndrome, neuroactive steroids and the brain. Gynecol. Endocrinol. (1999) 13(3):206–220.
   PubMed Web of Science ®Google Scholar
• GIRDLER SS, STRANEVA PA, LIGHT KC, PEDERSON CA, MORROW AL: Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol. Psych. (2001) 49(9):788–797.
   PubMed Web of Science ®Google Scholar
• THYS-JACOBS S: Micronutrients and the premenstrual syndrome: the case for calcium. J. Am. Coll. Nutr. (2000) 19(2):220–227.
   PubMed Web of Science ®Google Scholar
• PARRY BL: Psychobiology of premenstrual dysphoric disorder. Semin. Reprod. Endocrinol. (1997) 15(1):55–68.
   PubMedGoogle Scholar
• PARRY BL, NEWTON RP: Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology (2001) 25(5, Suppl. 1):S102–S108.
   Google Scholar
• HALBREICH U, TWOREK H: Altered serotonergic activity in women with dysphoric premenstrual syndromes. Intl Psych. Med. (1993) 23(1):1–27.
   PubMed Web of Science ®Google Scholar
• MARCH D, PEARLSTEIN TB, YONKERS KA: Treatment of premenstrual dysphoric disorder. Psychiatr. Clin. NorthAm. Ann. Drug Ther. (2001) 8:89–108.
   Google Scholar
• PARRY BL: The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications. CNS Drugs (2001) 15(4):277–285.
   PubMed Web of Science ®Google Scholar
• STEINER M, PEARLSTEIN T: Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J.
   Google Scholar
• GRIFFIN LD, MELLON SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA (1999)31.96(23):13512–13517.
   Google Scholar
• GUIDOTTI A, COSTA E: Can the antidysphoric and amdolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol. Psych.32.(1998) 44(9):865–873.
   Google Scholar
• VEENINGA AT, WESTENBERG HG, WEUSTEN JT: Fluvoxamine in the treatment of menstrually related mood disorders. Psychopharmacology (Berl) (1990) 102(3):414–416.
   PubMed Web of Science ®Google Scholar
• DIMMOCK PW, WYATT KM, JONES33.PW, O'BRIEN PM: Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet (2000) 356(9236):1131–1136.
   Google Scholar
• YONKERS KA, HALBREICH U, FREEMAN E et al.: Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA (1997) 278(12):983–988.35. syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. °Enter Gynecol. (1990) 76(2):302–307.
   Google Scholar
• FREEMAN EW, RICKELS K, SONDHEIMER SJ, POLANSKY M: Differential response to antidepressants in women with premenstrual syndrome/ premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psych. (1999) 56(10):932–939.
   PubMed Web of Science ®Google Scholar
• HALBREICH U, SMOLLER JW: Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J. Cliii. Psych. (1997) 58(9):399–402.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, ARREDONDO F, KAO L-C, POLLACK SE, SONDHEIMER SJ: Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. Clin. Psychopharmacol. (1999) 19(1):3–8.
   PubMed Web of Science ®Google Scholar
• JERMAIN DM, PREECE CK, SYKES RL, KUEHL TJ, SULAK PJ: Luteal phase sertraline treatment for premenstrual dysphoric disorder. Arch. Fam. Med. (1999) 8(4):328–332.
   PubMedGoogle Scholar
• YOUNG SA, HURT PH, BENEDEK DM, HOWARD RS: Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. Clin. Psych. (1998) 59(2):76–80.
   Google Scholar
• ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBLAD C: The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsycho-pharmacology (1995) 12(2):167–176.
   PubMed Web of Science ®Google Scholar
• WIKANDER I, SUNDBLAD C, ANDERSCH B et al.: Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? Clin. Psychopharmacol. (1998) 18(5):390–398.
   Web of Science ®Google Scholar
• PEARLSTEIN TB, STONE AB, LUND SA, SCHEFT H, ZLOTNICK C, BROWN WA: Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J. Psychopharmacol. (1997) 17(4):261–266.
   Web of Science ®Google Scholar
• SUNDBLAD C, MODIGH K, ANDERSCH B, ERIKSSON E: Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr. Scand. (1992) 85(1):39–47.
   PubMed Web of Science ®Google Scholar
• SUNDBLAD C, HEDBERG MA, ERIKSSON E: Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsycho-pharmacology (1993) 9(2):133–145.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, YONKERS KA, KUNZ NR, MCPHERSON MK, UPTON GV: Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gyncecol. (2001) 98(5, Part 1):737–744.
   Google Scholar
• STEINBERG S, ANNABLE L, YOUNG SN, LIYANAGE N: A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol. Psych. (1999) 45(3):313–320.
   PubMed Web of Science ®Google Scholar
• BRZEZINSKI AA, WURTMAN JJ, WURTMAN RJ, GLEASON R, GREENFIELD J, NADER T: d-fen-fluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet. Gynecol. (1990) 76(2):296–301.
   PubMed Web of Science ®Google Scholar
• LANDEN M, ERIKSSON O, SUNDBLAD C, ANDERSCH B, NAESSEN T, ERIKSSON E: Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) (2001) 155(3):292–298.
   PubMed Web of Science ®Google Scholar
• ERIKSSON E: Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. kit. Clin. Psychopharmacol (1999) 14\(Suppl. 2):S27–S33.
   Google Scholar
• ALTSHULER LL, COHEN LS, MOLINE ML, KAHN DA, CARPENTER D, DOCHERTY JP: The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad. Med. (2001) Spec. No.:1–107.
   Google Scholar
• AMERICAN COLLEGE OF OBSTETRICS AND GYNECOLOGY: Premenstrual Syndrome. ACOG Practice Bulletin. American College of Obstetrics and Gynecology, Washington, DC, USA (2000).
   Google Scholar
• PEARLSTEIN T, STEINER M: Non-antidepressant treatment of premenstrual syndrome. j. Clin. Psych. (2000) 61 (Suppl. 12):22–27.
   Google Scholar
• STEVINSON C, ERNST E: Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. Am. Obstet. Gynecol (2001) 185(1):227–235.
   PubMed Web of Science ®Google Scholar
• BLIER P: Possible neurobiological mechanisms underlying faster onset of antidepressant action.j Clin. Psych. (2001) 62\(Suppl. 4):7–11.
   Google Scholar
• STAHL SM: Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. Clin. Psych. (1998) 59\(Suppl. 4):5–14.
   Google Scholar
• HIEMKE C, HARTTER S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther: (2000) 85(1):11–28.
   PubMed Web of Science ®Google Scholar
• SERRA M, PISU MG, MUGGIRONI M et al.: Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmacology. (2001) 158(1):48–54.
   PubMed Web of Science ®Google Scholar
• COHEN LS, MINER C, BROWN E et al: Premenstrual daily fluoxetine for PMDD: A placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol (2002). In Press.
   Google Scholar
• STEINER M, HASKETT RF, CARROLL BJ: Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr. Scand. (1980) 62(2):177–190.
   PubMed Web of Science ®Google Scholar
• MCGAHUEY CA, GELENBERG AJ, LAUKES CA et al.: The Arizona Sexual Experience Scale (ASEX): reliability and validity. Sex Marital Ther. (2000) 26(1):25–40.
   Google Scholar
• STEINER M, KORZEKWA M, LAMONT J, WILKINS A: Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. (1997) 33(4):771–774.
   PubMedGoogle Scholar
• MINER C, BROWN E, MCCRAY S, GONZALES J, WOHLREICH M: Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Gin. Ther. (2002) 24(3):417–433.
   Google Scholar
• GUY W: ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, US Department of Health, Education and Welfare, Rockville, MD, USA (1976).
   Google Scholar
• LEON AC, OLFSON M, PORTERA L, FARBER L, SHEEHAN DV: Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int. Psych Med. (1997) 27(2):93–105.
   PubMed Web of Science ®Google Scholar
• BRANDENBURG S, TUYNMAN-QUA H, VERHEIJ R, PEPPLINKHUIZEN L: Treatment of premenstrual syndrome with fluoxetine: an open study. Int. Clin. Psychopharmacol (1993) 8(4):315–317.
   PubMed Web of Science ®Google Scholar
• ELKS ML: Open trial of fluoxetine therapy for premenstrual syndrome. South. Med. (1993) 86(5):503–507.
   Google Scholar
• RICKELS K, FREEMAN EW, SONDHEIMER S, ALBERT J: Fluoxetine in the treatment of premenstrual syndrome. Carr. Therapeutic Res. (1990) 48(1):161–166.
   Web of Science ®Google Scholar
• DIEGOLI MS, DA FONSECA AM, DIEGOLI CA, PINOTTI JA: A double-blind trial of four medications to treat severe premenstrual syndrome. Int. Gynaecol Obstet. (1998) 62(1):63–67.
   PubMed Web of Science ®Google Scholar
• ROMANO S, JUDGE R, DILLON J, SHULER C, SUNDELL K: The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Clin. Ther. (1999) 21(4):615–633.
   PubMed Web of Science ®Google Scholar
• STEINER M, STEINBERG S, STEWART D et al.: Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl. I Med. (1995) 332(23):1529–1534.
   PubMed Web of Science ®Google Scholar
• STEINER M, STREINER DL, STEINBERG S et al.: The measurement of premenstrual mood symptoms. Affect. Disord. (1999) 53(3):269–273.
   PubMed Web of Science ®Google Scholar
• STEINER M, ROMANO SJ, BABCOCK S et al.: The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder. BLOC (2001) 108(5):462–468.
   Google Scholar
• WOOD SH, MORTOLA JF, CHAN YF, MOOSSAZADEH F, YEN SS: Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet. Gynecol (1992) 80(3, Part 1):339–344.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (Revived). American Psychiatric Press, Inc. Washington, DC, USA (1987).
   Google Scholar
• MENKES DB, TAGHAVI E, MASON PA, HOWARD RC: Fluoxetine's spectrum of action in premenstrual syndrome. Int. Clin. Psychopharmacol (1993) 8(2):95–102.
   PubMed Web of Science ®Google Scholar
• SU TP, SCHMIDT PJ, DANACEAU MA et al.: Fluoxetine in the treatment of premenstrual dysphoria. Neuropsycho-pharmacology (1997) 16(5):346–356.
   PubMed Web of Science ®Google Scholar
• OZEREN S, CORAKCI A, YUCESOY I, MERCAN R, ERHAN G: Fluoxetine in the treatment of premenstrual syndrome. Ear: Obstet. Gynecol Reprod. Biol. (1997) 73(2):167–170.
   PubMed Web of Science ®Google Scholar
• STONE AB, PEARLSTEIN TB, BROWN WA: Fluoxetine in the treatment of late luteal phase dysphoric disorder. I. Clin. Psych. (1991) 52(7):290–293.
   Google Scholar
• ENDICOTT J, SPITZER RL, FLEISS JL, COHEN J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psych. (1976) 33(6):766–771.
   PubMed Web of Science ®Google Scholar
• HAMILTON M: A rating scale for depression. I Neurol Neurosurg. Psych. (1960) 23:56–62.
   PubMed Web of Science ®Google Scholar
• PEARLSTEIN TB, STONE AB: Long-term fluoxetine treatment of late luteal phase dysphoric disorder. I. Clin. Psych. (1994) 55(8):332–335.
   Google Scholar
• DE LA GANDARA MARTIN JJ: Premenstrual dysphoric disorder: long-term treatment with fluoxetine and discont-inuation. Actas Luso Esp. Neurol Psiquiatr. Cienc. Afines. (1997) 25(4):235–242.
   PubMedGoogle Scholar
• ANDERSON IM: Meta-analytical studies on new antidepressants. Br. Med. Bull. (2001) 57:161–178.
   PubMed Web of Science ®Google Scholar
• BEASLEY CM JR., KOKE SC, NILSSON ME, GONZALES JS: Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin. The]: (2000) 22(11):1319–1330.
   PubMed Web of Science ®Google Scholar
• CALIL HM: Fluoxetine: a suitable long- term treatment.Psych. (2001)62\(Suppl. 22):24–29.
   Google Scholar
• ZAJECKA J, AMSTERDAM JD, QUITKIN FM et al.: Changes in adverse events reported by patients during 6 months of fluoxetine therapy.' Clin. Psych. (1999) 60(6):389–394.
   Google Scholar
• GOLDSTEIN BJ, GOODNICK PJ: Selective serotonin reuptake inhibitors in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics. Psychepharmacel (1998) 12(3, Suppl. B):555–587.
   Google Scholar
• SUNDSTROM-POROMAA I, BIXO M, BJORN I, NORDH O: Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. Psychesem. °Enter Cynaecel (2000) 21(4):205–211.
   Google Scholar
• BALDWIN DS: Depression and sexual dysfunction. Br. Med. Bull. (2001) 57:81–99.
   PubMed Web of Science ®Google Scholar
• FERGUSON JM: The effects of antidepressants on sexual functioning in depressed patients: a review. J. Clin. Psych. (2001) 62\(Suppl. 3):22–34.
   Google Scholar
• ROSEN RC, LANE RM, MENZA M: Effects of SSRIs on sexual function: a critical review.' Clin. Psychepharmacel (1999) 19(1):67–85.
   Google Scholar
• SUSSMAN N, GINSBERG D: Rethinking side effects of the selective serotonin reuptake inhibitors: sexual dysfunction and weight gain. Psych. Ann. (1998) 28(2):89–97.
   Web of Science ®Google Scholar
• ZAJECKA J: Strategies for the treatment of antidepressant-related sexual dysfunction. Clin. Psych. (2001) 62\(Suppl. 3):35–43.
   Google Scholar
• MONTEJO AL, LLORCA G, IZQUIERDO JA, RICO-VILLA-DEMOROS F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.Psych. (2001)62\(Suppl. 3):10–21.
   Google Scholar
• ZAJECKA J, MITCHELL S, FAWCETT J: Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychepharmacel Bull. (1997)100. 33(4):755–760.
   Google Scholar
• COLEMAN CC, KING BR, BOLDEN-WATSON C et al: A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release101.and fluoxetine. Clin. The]: (2001) 23(7):1040–1058.
   Google Scholar
• FAVA M: Weight gain and antidepressants. Clin. Psych. (2000) 61 (Suppl. 11):37–41.
   Google Scholar
• HARVEY BH, BOUWER CD:102.Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Gin. Neurepharmacel (2000) 23(2):90–97.103.
   Google Scholar
• MASAND PS: Weight gain associated with psychotropic drugs. Expert Opin. Pharmacether. (2000) 1(3):377–389.104.
   Google Scholar
• MICHELSON D, AMSTERDAM JD, QUITKIN FM et al.: Changes in weight during a 1-year trial of fluoxetine. Am. Psych. (1999) 156(8):1170–1176.
   Google Scholar
• FAVA M, JUDGE R, HOOG SL, NILSSON ME, KOKE SC: Fluoxetine105.versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J. Clin. Psych. (2000)106.61(11):863–867.
   Google Scholar
• ZAJECKA J, TRACY KA, MITCHELL S: Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a107.literature review. Clin. Psych. (1997) 58(7):291–297.
   Google Scholar
• HADDAD PM: Antidepressant108.discontinuation syndromes. Drug Sal (2001) 24(3):183–197.
   Google Scholar
• MOURILHE P, STOKES PE: Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression. Drug Sal (1998) 18(1):57–82.109.
   Google Scholar
• NEMEROFF CB, DEVANE CL, POLLOCK BG: Newer antidepressants and the cytochrome P450 system. Am. Psych. (1996) 153(3):311–320.
   Google Scholar
• ADDIS A, KOREN G: Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psyche]. Med. (2000) 30(1):89–94.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, SUNDELL K: A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Human Psychepharmacel (1999) 14:319–324.
   Web of Science ®Google Scholar
• WISNER KL, GELENBERG AJ, LEONARD H, ZARIN D, FRANK E: Pharmacologic treatment of depression during pregnancy. JAMA (1999) 282 (13):1264–1269. 110.
   Google Scholar
• CHAMBERS CD, JOHNSON KA, DICK LM, FELIX RJ, JONES KL: Birth outcomes in pregnant women taking fluoxetine. N Engl. I Med. (1996) 335(14):1010–1015.
   PubMed Web of Science ®Google Scholar
• COHEN LS, HELLER VL, BAILEY JVV, GRUSH L, ABLON JS, BOUFFARD SM: Birth outcomes following prenatal exposure to fluoxetine. Biel. Psych. (2000) 48(10):996–1000.
   PubMed Web of Science ®Google Scholar
• MHANNA MJ, BENNET JB, IZATT SD: Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics (1997) 100(1):158–159.
   PubMed Web of Science ®Google Scholar
• MOHAN CG, MOORE JJ: Fluoxetine toxicity in a preterm infant. Perinatel (2000) 20(7):445–446.
   PubMedGoogle Scholar
• NORDENG H, LINDEMANN R, PERMINOV KV, REIKVAM A: Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. (2001) 90(3):288–291.
   PubMed Web of Science ®Google Scholar
• SPENCER MJ: Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics (1993) 92(5):721–722.
   PubMed Web of Science ®Google Scholar
• NULMAN I, ROVET J, STEWART DE et al.: Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl. Med. (1997) 336(4):258–262.
   PubMed Web of Science ®Google Scholar
• HALE TW, SHUM S, GROSSBERG M: Fluoxetine toxicity in a breastfed infant. Clin. Pediatr. (2001) 40(12):681–684.
   PubMed Web of Science ®Google Scholar
• LESTER BM, CUCCA J, ANDREOZZI L, FLANAGAN P, OH W: Possible association between fluoxetine hydrochloride and colic in an infant. Am. Acad. Child Adelesc. Psych. (1993) 32(6):1253–1255.
   PubMed Web of Science ®Google Scholar
• KRISTENSEN JH, ILETT KF, HACKETT LP, YAPP P, PAECH M, BEGG EJ: Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br. Gin. Pharmacy]. (1999) 48(4):521–527.
   Web of Science ®Google Scholar
• HENDRICK V, STOWE ZN, ALTSHULER LL et al.: Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biel Psych. (2001) 50(10):775–782.
   PubMed Web of Science ®Google Scholar
• BURT VK, SURI R, ALTSHULER L, STOWE Z, HENDRICK VC, MUNTEAN E: The use of psychotropic medications during breast-feeding. Am.' Psych. (2001) 158(7):1001–1009.
   Google Scholar
• BORYS DJ, SETZER SC, LING LJ, REISDORF JJ, DAY LC, KRENZELOK EP: Acute fluoxetine overdose: a report of 234 cases. Am. Emerg. Med. (1992) 10(2):115–120.
   PubMed Web of Science ®Google Scholar
• PHILLIPS S, BRENT J, KULIG K, HEILIGENSTEIN J, BIRKETT M: Fluoxerine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. The Antidepressant Study Group. I Emerg. Med. (1997) 15(4):439–445.
   Google Scholar
• FRANK L, REVICKI DA, SORENSEN SV, SHIH YC: The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs (2001) 15(1):59–83.
   PubMed Web of Science ®Google Scholar
• WILDE MI, BENFIELD P: Fluoxetine. A pharmacoeconomic review of its use in depression. Pharmarveconumics (1998) 13(5):543–561.
   Google Scholar
• CROWN WH, TREGLIA M, MENEADES L, WHITE A: Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health (2001) 4(4):295–307.
   PubMedGoogle Scholar
• HYLAN TR, SUNDELL K, JUDGE R: The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. Whitens Health Gend. Based Med. (1999) 8(8):1043–1052.
   PubMed Web of Science ®Google Scholar
• ROBINSON RL, SWINDLE RW: Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. j. Womens Health Gend. Based Med. (2000) 9(7):757–768.
   PubMed Web of Science ®Google Scholar
• WITTCHEN HU, BECKER E, LIEB R, KRAUSE P: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psycho]. Med. (2002) 32(1):119–132.
   PubMed Web of Science ®Google Scholar
• WEISSMAN MM, BOTH WELL S: Assessment of social adjustment by patient self-report. Arch. Gen. Psych. (1976) 33(9):1111–1115.
   PubMed Web of Science ®Google Scholar
• PEARLSTEIN TB, HALBREICH U, BATZAR ED et al.: Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J. Clio. Psych. (2000) 61(2):101–109.
   PubMed Web of Science ®Google Scholar